Enhancing the company's overall capabilities in high containment manufacturing
Johnson Matthey, a provider of pharmaceutical services, active pharmaceutical ingredients (APIs) and catalyst technologies, has completed and commissioned a new high containment facility for potent product manufacture at its Macfarlan Smith plant in Edinburgh.
Macfarlan Smith is an established provider of opiates, controlled substance and highly potent products and the new self-contained, state-of-the-art facility is required to meet existing demand for potent products while providing additional capacity to meet potential future requirements.
This new facility is a significant addition to our existing capabilities at our site in Edinburgh
The facility features isolators containing a range of Hastelloy and glass vessels, with powder transfers being mediated through split butterfly values with active valve wash stations. It also contains a dedicated finishing room, QC laboratory and control room. Overall the facility design ensures a safe working environment and has the necessary manufacturing controls and procedures in place to produce compounds with OEL less than 30ng per m3.
'This new facility is a significant addition to our existing capabilities at our site in Edinburgh,' said Steve Barr, Vice President Business Development Europe at Johnson Matthey. 'It enhances our overall capabilities in high containment manufacturing and provides extra capacity to extend our range of high potency products and services. These facilities support Johnson Matthey’s broader assets for the manufacture of highly potent products including our US capacity in West Deptford, NJ and Devens, MA.'
The commissioning of the facility was completed in February and commercial manufacturing is now due to start.